( The safety profile of liraglutide in our cohort was consistent with previous pediatric randomized controlled trials (RCTs), with adverse events (AEs) predominantly mild and gastrointestinal in nature, including nausea, vomiting, and diarrhea, reported in 43.6% of participants ( Despite these favorable outcomes, the discontinuation rate during the dose-escalation phase was relatively high (25.6%), mirroring patterns observed in other pediatric liraglutide trials where treatment withdrawal often occurred during the initial weeks, coinciding with peak gastrointestinal symptoms ( A key strength of this study lies in its conduct within a publicly funded healthcare system, entirely independent of pharmaceutical industry sponsorship, thereby enhancing both methodological rigor and external validity
The MHRA has issued warnings about unlicensed peptide products sold online due to concerns about quality, safety, contamination, and lack of regulatory oversight
Continue your research Need a structured template for post-operative wound documentation
Some stimulate growth hormone to trigger lipolysis directly
